Abilify and Raynaud's phenomenon - a phase IV clinical study of FDA data

Summary:

Raynaud's phenomenon is reported as a side effect among people who take Abilify (aripiprazole), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Lexapro, and have Attention deficit hyperactivity disorder.

The phase IV clinical study analyzes which people have Raynaud's phenomenon when taking Abilify. It is created by eHealthMe based on reports of 97,308 people who have side effects when taking Abilify from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,454 Abilify users. Check the latest studies of Abilify.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 634 drugs and 995 conditions by eHealthMe. Check the latest studies of Raynaud's phenomenon.

On May, 14, 2026

97,308 people reported to have side effects when taking Abilify.
Among them, 59 people (0.06%) have Raynaud's phenomenon.

Could Abilify cause Raynaud's phenomenon?

Among these 59 people:

How long have people been on Abilify when they have Raynaud's phenomenon? *

What is the gender of people who have Raynaud's phenomenon when taking Abilify? *

female: 83.64 %
male: 16.36 %

What is the age of people who have Raynaud's phenomenon when taking Abilify? *

What are other drugs people take besides Abilify? *

What are other side effects people have besides Raynaud's phenomenon? *

Skin Discoloration - Bluish (bluish colour of skin): 28 people, 47.46%
Axonal Neuropathy (dysfunction of axon nerves): 27 people, 45.76%
Idiopathic Or Primary Livedo Reticularis (netlike pattern of reddish-blue skin discoloration, usually on the legs): 27 people, 45.76%
Fatigue (feeling of tiredness): 7 people, 11.86%
Pain: 7 people, 11.86%
Migraine (headache): 6 people, 10.17%
High Blood Pressure: 6 people, 10.17%
Back Pain: 6 people, 10.17%
Peripheral Swelling: 5 people, 8.47%
Back Injury: 5 people, 8.47%

What are the existing conditions these people have? *

Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 25 people, 42.37%
Psychomotor Hyperactivity (feelings of extreme restlessness): 21 people, 35.59%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 8.47%
Agitation (state of anxiety or nervous excitement): 4 people, 6.78%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 6.78%
Stress And Anxiety: 2 people, 3.39%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 3.39%
Abnormal Behavior: 2 people, 3.39%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 3.39%
Personality Disorder: 1 person, 1.69%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Raynaud's phenomenon?

- Check whether Raynaud's phenomenon is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abilify:

Abilify (101,454 reports)

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Raynaud's phenomenon:

Raynaud's phenomenon (634 drugs)

Browse all the conditions that are associated with Raynaud's phenomenon:

Raynaud's phenomenon (995 conditions)

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.